Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11963154 | 0.85 | CYP11B1 (0.47) | CYP11B1CYP11B2TRPV4PLA2G7 | |
| SCHEMBL7323185 | 0.83 | CYP11B1 (0.65) | CYP11B1CYP11B2TRPV4MAOB | |
| SCHEMBL19128162 | 0.81 | TRPV4 (0.48) | CYP11B1CYP11B2TRPV4MAOB | |
| SCHEMBL2539990 | 0.80 | CYP11B1 (0.58) | CYP11B1CYP11B2TRPV4MAOB | |
| SCHEMBL9244079 | 0.80 | CYP11B1 (0.51) | CYP11B1CYP11B2TRPV4MAOBPLA2G7 | |
| SCHEMBL13481174 | 0.80 | CYP11B1 (0.51) | CYP11B1CYP11B2TRPV4MAOBPLA2G7 | |
| SCHEMBL11963218 | 0.79 | TRPV4 (0.48) | CYP11B1CYP11B2TRPV4 | |
| SCHEMBL188561 | 0.78 | MAOB (0.55) | CYP11B1CYP11B2MAOB | |
| SCHEMBL8123834 | 0.78 | MAOB (0.45) | MAOB | |
| SCHEMBL31697317 | 0.78 | MAOB (0.45) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0669920-B1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | AVENTIS PHARMA INC (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6046203-A | USEFUL FOR THE TREATMENT OF VARIOUS MEMORY DYSFUNCTIONS CHARACTERIZED BY A DECREASED CHOLINERGIC FUNCTION SUCH AS ALZHEIMER'S DISEASE; ALSO INHIBIT MONOAMINE OXIDASE AND HENCE ARE USEFUL AS ANTIDEPRESSANTS | AVENTIS PHARMACEUTICALS INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5925766-A | COGNITION ACTIVATORS FOR DECREASING CHOLINERGIC FUNCTION OF ALZHEIMER*S DISEASE AND ARE ENZYME INHIBITORS OF MONOAMINE OXIDASE AND ARE ANTIDEPRESSANTS | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5756754-A | Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds | HOECHST MARION ROUSSEL, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5580982-A | ANTIDEPRESSANTS; ANTICHOLINERGIC AGENTS; ALZHEIMER'S DISEASE; AMINE OXIDASE INHIBITORS | HOECHST MARION ROUSSEL INC. (US) | 1996-12-03 | — | — | US | disclosed |
| US-5494908-A | ANTIDEPRESSANT | HOECHST-ROUSSEL PHARMACEUTICAL INCORPORATED (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0669920-A4 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS. | HOECHST ROUSSEL PHARMA (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0669920-A1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | HOECHST MARION ROUSSEL, Inc. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994012495-A1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-06-09 | — | — | WO | disclosed |